Merrill Lynch is running a biotech tracker based on 20 of the US and Europe's leading stocks in the ...
Merrill Lynch is running a biotech tracker based on 20 of the US and Europe's leading stocks in the sector. The investment vehicle offers investors the chance to buy certificates whose value is re-adjusted using quantitative guidelines to reflect the performance of the Dynamic BioTech20 index every four months. Among the businesses it follows are North American stocks Biogen and Human Genome Sciences, UK companies Celltech and Shire Pharmaceuticals Group, and Dutch company Qiagen. Since the start of 1999 to 1 April 2000 the index has outperformed the Nasdaq Composite Index by about 23%. ...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes